HOYNG ROKH MONEGIER
We only have limited information for this firm. Consider the following firms which have provided more information:
HOYNG ROKH MONEGIER‘s ’talented, highly responsive, and very knowledgeable’ team handles complex instructions on behalf of life sciences, telecoms and electronics sector clients, with experience taking on multi-jurisdictional patent disputes and assisting with patent prosecutions and portfolio management. Leading the team is Bart van den Broek, whose practice is centred on tech patents and comprises both cross-border litigation and patent protection strategies, with co-founding partner Willem Hoyng acting for a range of domestic and international pharmaceutical and biotech clients. Theo Blomme maintains a broad practice that includes both tech and pharmaceutical patent disputes, with Peter van Schijndel specialising in biotech, pharmaceutical and medical devices matters. Simon Dack departed the firm in July 2023.
Legal 500 Editorial commentary
Testimonials
Collated independently by Legal 500 research team.
'Their experience before The Hague patent court is their strong point.'
'Theo Blomme is very alert in court and can immediately respond to opponents' invalid arguments during hearings.'
Abbreviated data is displayed for this firm.
Key clients
- Johnson & Johnson (Janssen Biologics)
- BioNTech
Abbreviated data is displayed for this firm.
Work highlights
- Defended BioNTech in patent litigation concerning mRNA Covid vaccines initiated by Moderna.
- Acted for Netflix in patent litigation initiated by DivX.
Abbreviated data is displayed for this firm.